Evidence map›Paper›PMID 33404803›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2021

Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents.

Go Saito, Takahiro Ebata, Tsukasa Ishiwata, Shunichiro Iwasawa, Ichiro Yoshino, Yuichi Takiguchi, Koichiro Tatsumi

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Go SaitoDepartment of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Takahiro EbataDivision of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan.
Tsukasa IshiwataDepartment of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Shunichiro IwasawaDepartment of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan. iwasawas@chiba-u.jp.ORCID http://orcid.org/0000-0003-2901-1646
Ichiro YoshinoDepartment of General Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yuichi TakiguchiDepartment of Medical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Koichiro TatsumiDepartment of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe risk factors for skeletal-related events (SREs) among non-small cell lung cancer (NSCLC) patients during treatment with bone-modifying agents (BMAs) are not yet well-understood.

methodsThe medical records of 238 consecutive NSCLC patients treated with BMAs, including zoledronic acid and denosumab, at the Chiba University Hospital from 2012 to 2016 were reviewed in the present study. SREs were defined as either pathologic fractures, spinal cord compression, the need for bone irradiation or surgery, or hypercalcemia. The risk factors for earlier occurrence of the first SRE from the time of the first bone metastasis diagnosis after the initiation of BMA treatment were identified.

resultsOf the 238 included patients, 92% (n = 220) had a performance status (PS) of 0-2 at diagnosis of bone metastasis. Forty-eight (20%) patients developed at least one SRE. The most common first SRE was the need for bone irradiation surgery (n = 27, 56%). Significant risk factors included poor PS (hazard ratio [HR]: 4.36; p = .024), male sex (HR: 2.17; p = .022), and the use of zoledronic acid (HR: 1.91; p = .032). The overall survival (OS) from the first bone metastasis diagnosis was 394 days (95% confidence interval [CI]: 331-465). The OS of patients with PS 3 and 4 at the diagnosis of bone metastasis (median: 36 days; 95% CI: 13-50) was significantly (p < 0.0001) shorter than that of patients with PS 0-2 (median: 411 days; 95% CI: 354-558) (HR: 4.53; 95% CI: 2.62-7.35).

conclusionsCareful observation is needed for patients with the identified risk factors, which include poor PS and male sex, despite the BMA treatment.

Indexed as

AdultAgedAged, 80 and overBone and BonesBone Density Conservation AgentsBone NeoplasmsCarcinoma, Non-Small-Cell LungDenosumabFemaleFractures, SpontaneousHumansHypercalcemiaLung NeoplasmsMaleMiddle AgedProportional Hazards ModelsBone Density Conservation AgentsDenosumabZoledronic AcidBone metastasisBone-modifying agentNon-small cell lung cancerRisk factorSkeletal-related event

Identifiers

PMID33404803

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.